Display options
Cite
Reimer P. New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat. Cancer Manag Res. 2015;7:145-51doi: 10.2147/CMAR.S85351.
Reimer, P. (2015). New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat. Cancer management and research, 7145-51. https://doi.org/10.2147/CMAR.S85351
Reimer, Peter. "New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat." Cancer management and research vol. 7 (2015): 145-51. doi: https://doi.org/10.2147/CMAR.S85351
Reimer P. New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat. Cancer Manag Res. 2015 Jun 03;7:145-51. doi: 10.2147/CMAR.S85351. eCollection 2015. PMID: 26082661; PMCID: PMC4461120.
Copy Download .nbib Format: NLM
Share it on

Cancer Manag Res. 2015 Jun 03;7:145-51. doi: 10.2147/CMAR.S85351. eCollection 2015.

New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.

Cancer management and research

Peter Reimer

Affiliations

  1. Clinic for Hematology, Medical Oncology and Stem Cell Transplantation, Evangelisches Krankenhaus Essen-Werden gGmbH, Essen, Germany.

PMID: 26082661 PMCID: PMC4461120 DOI: 10.2147/CMAR.S85351

Abstract

Peripheral T-cell lymphomas (PTCL) represent a heterogeneous group of rare malignancies that with the exception of anaplastic lymphoma kinase expressing anaplastic large cell lymphoma, share a poor outcome after standard (eg, anthracycline-based) chemotherapy. Most patients are either refractory to initial therapy or eventually relapse. Randomized studies for relapsed/refractory PTCL are not available, however, recently published data show that conventional chemotherapy has very limited efficacy in the salvage setting. Thus, novel drugs are urgently needed to improve the outcome in this setting. Belinostat, a pan-histone deacetylase inhibitor, has demonstrated meaningful efficacy and a favorable toxicity profile in two single-arm Phase II trials on 153 patients with relapsed/refractory PTCL. The conclusive results led to an accelerated approval by the US Food and Drug Administration. The present review summarizes the clinical data available for belinostat, its current role, and future perspectives.

Keywords: T-cell lymphoma; belinostat; relapsed/refractory; treatment

References

  1. Leukemia. 2006 Sep;20(9):1533-8 - PubMed
  2. J Clin Oncol. 2004 Jun 1;22(11):2172-6 - PubMed
  3. J Clin Oncol. 2012 Sep 1;30(25):3093-9 - PubMed
  4. Ann Oncol. 2008 May;19(5):958-63 - PubMed
  5. Ai Zheng. 2004 Nov;23(11 Suppl):1443-7 - PubMed
  6. Clin Cancer Res. 2009 Jun 15;15(12):3918-26 - PubMed
  7. Expert Opin Investig Drugs. 2009 Apr;18(4):501-8 - PubMed
  8. J Hematol Oncol. 2013 Sep 10;6:69 - PubMed
  9. J Clin Oncol. 2013 Jun 1;31(16):1970-6 - PubMed
  10. J Clin Oncol. 2012 Feb 20;30(6):631-6 - PubMed
  11. J Clin Oncol. 1989 Dec;7(12):1783-90 - PubMed
  12. Ann Oncol. 1997 Jun;8(6):583-92 - PubMed
  13. Cancer. 1993 Sep 1;72(5):1762-72 - PubMed
  14. Blood. 1999 Jun 1;93(11):3913-21 - PubMed
  15. Br J Haematol. 2005 Aug;130(4):561-7 - PubMed
  16. Br J Haematol. 2015 Mar;168(6):811-9 - PubMed
  17. J Clin Oncol. 2009 Aug 20;27(24):3951-8 - PubMed
  18. J Clin Oncol. 2011 Mar 20;29(9):1182-9 - PubMed
  19. Eur J Cancer. 2002 Jan;38(1):75-81 - PubMed
  20. Bone Marrow Transplant. 2012 Jan;47(1):65-72 - PubMed
  21. J Clin Oncol. 2008 Sep 1;26(25):4124-30 - PubMed
  22. Blood. 1998 Jul 1;92(1):76-82 - PubMed
  23. Clin Cancer Res. 2008 Feb 1;14(3):804-10 - PubMed
  24. J Clin Oncol. 2009 Jan 1;27(1):106-13 - PubMed
  25. Br J Cancer. 2009 Mar 10;100(5):758-63 - PubMed
  26. Cancer Chemother Pharmacol. 2011 Jun;67(6):1273-9 - PubMed
  27. Leukemia. 2012 Mar;26(3):520-6 - PubMed
  28. J Clin Oncol. 2008 May 10;26(14):2264-71 - PubMed
  29. Eur J Haematol. 2008 Sep;81(3):170-6 - PubMed
  30. Ann Oncol. 2011 Jul;22(7):1608-13 - PubMed
  31. Blood. 1997 Jun 15;89(12):4514-20 - PubMed
  32. J Hematol Oncol. 2014 Jan 23;7:11 - PubMed
  33. BMC Cancer. 2012 Jun 08;12:226 - PubMed
  34. Biol Blood Marrow Transplant. 2013 Apr;19(4):602-6 - PubMed
  35. Br J Cancer. 2010 Jun 29;103(1):12-7 - PubMed
  36. Ann Oncol. 2002 Jan;13(1):140-9 - PubMed
  37. Blood. 1999 Apr 15;93(8):2697-706 - PubMed
  38. Ann Oncol. 1990;1(1):45-50 - PubMed
  39. Blood. 1997 Jun 1;89(11):3909-18 - PubMed
  40. Eur J Haematol. 2007 Jul;79(1):32-8 - PubMed
  41. Ann Oncol. 1998 Aug;9(8):849-55 - PubMed
  42. J Clin Oncol. 2012 Jun 20;30(18):2190-6 - PubMed
  43. Bone Marrow Transplant. 2005 Aug;36(3):271-3 - PubMed
  44. Cancer. 1984 Aug 15;54(4):687-96 - PubMed

Publication Types